MEMORIAL SLOAN-KETTERING CANCER CENTER 
Dr. Donald S. Fredrickson 
Director, 
National Institute of Health 
Building 1 room 124 
900 Rockville Pike 
Bethesda, lid. 20014 
Dear Dr. Fredrickson: 
I have read the revised guidlines for DNA recombinant research and 
wish to express my support and appreciation for your efforts in this 
area of medical research. 
As an investigator in human genetics, I have a deep interest in 
seeing that these studies continue with due consideration to safety 
measurements. In my opinion, the new guidelines, as they have been 
developed, fulfill these goals. 
The fact that genetic research now allows us to realistically 
speculate that genetic defects can be corrected at the chromosomal 
level has made DNA recombinant research an important area to persue. 
Unfortunately, this has to some extent, been misinterpreted by the 
public and by some scientists. The new guidelines do, however, in 
my opinion, assure the public and the scientific community that such 
research can continue safely and rapidly. 
1275 YORK AVENUE, NEW YORK, NEW YORK 10021 
(212) 794-6005 
=(21 2) 794-7541 
September 26, 1978 
BD/lsh 
Bo Dupont, M.D. 
Professor of Biology 
/ 
Cornell Graduate School 
of Medical Sciences 
Member, Sloan-Kettering Institute 
for Cancer Research 
[A-388] 
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 
SLOAN-KETTERING DIVISION, GRADUATE SCHOOL OF MEDICAL SCIENCES. CORNELL UNIVERSITY 
